

BRITISH SARCOMA GROUP

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

BRITISH SARCOMA GROUP

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 17

BRITISH SARCOMA GROUP

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2022

Trustees

Mr P Cool
Dr A Dangoor, President
Mr A Desai (appointed 22 March 2022)
Dr I Fragkandrea-Nixon
Dr S Furtado (appointed 6 June 2022)
Mr C Gerrand
Mr A Hayes
Professor I Judson (resigned 13 December 2021)
Ms A Z McCarthy
Ms C A Millman (appointed 6 June 2022)
Mrs A Pabla
Dr B Seddon (resigned 5 September 2022)
Mr O Tilsley

Charity registered number

1154928

Principal office

Unit 14 The Stottie Shed
Baker's Yard
Christon Road
Newcastle upon Tyne
NE3 1XD

Secretary

Echo Events & Association Management

Accountants

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

Bankers

Lloyds Bank Plc
Ariel House
2138 Coventry Road
Sheldon
Birmingham
B26 3JW

BRITISH SARCOMA GROUP

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022

The Trustees present their annual report together with the financial statements of the charity for the year from 1 April 2021 to 31 March 2022.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Objectives and activities

● Policies and objectives

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the charity commission relating to public benefit.

The objectives of the British Sarcoma Group are: -

1. the relief of sickness by maintaining and advancing the education of medical, nursing and healthcare professionals in the United Kingdom concerned with the treatment and care of patients with bone and soft tissue sarcomas, through the provision of information, training and the identification of best practice;
2. the relief of sickness by the promotion of excellence in the healthcare and the treatment of patients with bone and soft tissue sarcoma, through enabling treatment specialists to identify and share best practice;
3. the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; and
4. to advance the education of the medical profession and the general public in all areas relating to sarcoma.

● Main activities undertaken to further the charity's purposes for the public benefit

Providing information about best practice in sarcoma treatment via the website, email updates, reports and other publications.

Running a programme of training and educational events (conferences, workshops, study days) to identify and share best practice.

Running scientific meetings.

Developing and promoting nationally-recognised and adopted clinical guidelines and service standards for the management of sarcoma.

Providing expert representation on sarcoma to the NHS through written responses and membership of advisory groups.

Developing projects to improve sarcoma healthcare and treatment.

Informing medical professionals about new research; promoting opportunities for research; commissioning research into best practice.

Providing information and training to generalist medical professionals about sarcoma.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

Objectives and activities (continued)

Working with other professional bodies and Royal Colleges to develop joint educational initiatives.

Working with national sarcoma patient organisations to raise awareness of sarcoma amongst public.

Achievements and performance

● Review of activities

The main achievements of the BSG in this financial year were to deliver the virtual annual conference, the major UK forum for multidisciplinary education in sarcoma. The Specialty Advisory Group chairs meetings were also supported. The BSG continues to develop nationally recognised clinical guidelines for the management of sarcoma.

Financial review

● Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. This is despite the effects of COVID-19 as delivery of educational workshops are to return to face to face events in the next financial year. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

● Reserves policy

The total funds of the charity at 31 March 2022 were £104,477.

The Board of Trustees have agreed it is necessary to maintain a level of reserves to cover the administration costs and the cost of staging the annual conference. This averages approximately £70,000 in total. The Trustees are pleased to note that the total funds exceed this figure and have plans to use these as explained in the future developments section of this Report.

● Overview

Income for the year totalled £101,195. The Statement of Financial Activities shows that the main source of income is sponsorship and delegate fees from the annual conference.

Delegate fees are shown under the general fund as unrestricted funds. Total delegate fees for the year were £59,020 (58.3% of total income).

Sponsorship income is restricted at the request of the donor. Total sponsorship for the year was £39,207 (38.7% of total income). A full breakdown of sponsors is given in the notes to the financial statements.

Expenditure for the year totalled £99,410 with the main item of charitable expenditure being in relation to the annual conference.

An operating surplus of £1,785 (previous year: deficit of £9,927) was made this year and increases the total general unrestricted funds of the charity at 31 March 2022 to £104,477 (previous period: £102,692).

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

Structure, governance and management

- **Constitution**

The British Sarcoma Group (BSG) is a Charitable Incorporated Organisation (CIO) registered in England and Wales with the Charity Commission on 8 December 2013 with registration number 1154928. Its governing document is its constitution, adopted on 22 May 2013.

- **Methods of appointment or election of Trustees**

Trustees are appointed by the existing Trustees for a three-year term which is extendable by mutual agreement of other Trustees with a maximum extension of a further three years. This is dependent on the skill set offered by the board member and the need to retain a wide range of key skills relevant to the continued success of the charity. New Trustees receive the BSG constitution, published financial statements, minutes of previous Board of Trustee meetings, as well as the Charity Commission guidance on effective governance.

Trustees meet on average three times a year in person or by teleconference.

- **Organisational structure and decision-making policies**

The day-to-day administration of the British Sarcoma Group and BSG conference management is delivered by Echo AM Limited.

- **Financial risk management**

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

Plans for future periods

In addition to the continuing activities referred to earlier in this Report the Trustees plan to spend funds in the 2021/22 year on a return to face to face educational workshops, including the annual conference, as initiatives to bring the sarcoma community together to optimise patient care.

BRITISH SARCOMA GROUP**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022****Statement of Trustees' responsibilities**

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 21 December 2022 and signed on their behalf by:

DocuSigned by:

F9792EEC5972467...

Dr A Dangoor
President

BRITISH SARCOMA GROUP**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2022****Independent examiner's report to the Trustees of British Sarcoma Group ('the charity')**

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 31 March 2022.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). This is in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed: 
Detlev Anderson FCA

Dated: 21 December 2022

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

BRITISH SARCOMA GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022

	Note	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:					
Charitable activities	3	61,988	39,207	101,195	32,250
Total income		61,988	39,207	101,195	32,250
Expenditure on:					
Charitable activities	5	60,203	39,207	99,410	42,177
Total expenditure		60,203	39,207	99,410	42,177
Net movement in funds		1,785	-	1,785	(9,927)
Reconciliation of funds:					
Total funds brought forward		102,692	-	102,692	112,619
Net movement in funds		1,785	-	1,785	(9,927)
Total funds carried forward		104,477	-	104,477	102,692

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

BALANCE SHEET
AS AT 31 MARCH 2022

	Note	2022 £	2021 £
Current assets			
Debtors	9	7,882	3,615
Cash at bank and in hand		143,518	103,432
		<u>151,400</u>	<u>107,047</u>
Creditors: amounts falling due within one year	10	(46,923)	(4,355)
Net current assets		<u>104,477</u>	<u>102,692</u>
Total assets less current liabilities		<u>104,477</u>	<u>102,692</u>
Total net assets		<u>104,477</u>	<u>102,692</u>
Charity funds			
Restricted funds	12	-	-
Unrestricted funds	12	104,477	102,692
Total funds		<u>104,477</u>	<u>102,692</u>

The financial statements were approved and authorised for issue by the Trustees on 21 December 2022 and signed on their behalf by:

DocuSigned by:

Adam Dangoor

F9792EEC5972467...

Dr A Dangoor
President

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1. General information

British Sarcoma Group is a charitable entity, charity number 1154928. The registered office is Unit 14, The Stottie Shed, Baker's Yard, Christon Road, Newcastle upon Tyne, NE3 1XD.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Sarcoma Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The charity has cash resources and no requirement for external funding. The Trustees have reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements. This is despite the effects of COVID-19 as delivery of educational workshops are to return to face to face events in the next financial year.

2.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

BRITISH SARCOMA GROUP**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022****2. Accounting policies (continued)****2.5 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.8 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

3. Income from charitable activities

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Delegate Fees	59,020	-	59,020
Exhibitor fees	2,968	-	2,968
Sponsorship - Immedica Pharma	-	14,995	14,995
Sponsorship - PolyNovo UK Limited	-	2,247	2,247
Sponsorship - Bayer Plc	-	8,500	8,500
Sponsorship - Takeda UK Ltd	-	5,995	5,995
Sponsorship - Blueprint Medicines	-	-	-
Sponsorship - GSK UK	-	-	-
Sponsorship - Karyopharm Therapeutics	-	-	-
Sponsorship - Stryker European Operations Ltd	-	2,500	2,500
Sponsorship - Boston Scientific Ltd	-	2,995	2,995
Sponsorship - IGEA Medical	-	1,975	1,975
Total 2022	61,988	39,207	101,195
	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Delegate Fees	11,250	-	11,250
Sponsorship - Immedica Pharma	-	6,000	6,000
Sponsorship - Bayer Plc	-	5,000	5,000
Sponsorship - Takeda UK Ltd	-	4,000	4,000
Sponsorship - Blueprint Medicines	-	2,000	2,000
Sponsorship - GSK UK	-	2,000	2,000
Sponsorship - Karyopharm Therapeutics	-	2,000	2,000
Total 2021	11,250	21,000	32,250

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

4. Analysis of grants

	Grants to Institutions 2022 £	Total funds 2022 £
	<i>Grants to Institutions 2021 £</i>	<i>Total funds 2021 £</i>
Grants, Annual conference	<u>1,450</u>	<u>1,450</u>

5. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Annual conference	<u>60,203</u>	<u>39,207</u>	<u>99,410</u>

	<i>Unrestricted funds 2021 £</i>	<i>Restricted funds 2021 £</i>	<i>Total 2021 £</i>
Annual conference	<u>21,190</u>	<u>20,987</u>	<u>42,177</u>

6. Analysis of expenditure by activities

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £
Annual conference	<u>74,282</u>	<u>25,128</u>	<u>99,410</u>

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

6. Analysis of expenditure by activities (continued)

	<i>Activities undertaken directly 2021 £</i>	<i>Grant funding of activities 2021 £</i>	<i>Support costs 2021 £</i>	<i>Total funds 2021 £</i>
Annual conference	26,118	1,450	14,609	42,177

Analysis of direct costs

	Annual conference 2022 £	Total funds 2022 £
Conference costs	54,282	54,282
Secretariat fees	20,000	20,000
	74,282	74,282

	<i>Annual conference 2021 £</i>	<i>Total funds 2021 £</i>
Conference costs	12,118	12,118
Secretariat fees	14,000	14,000
	26,118	26,118

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

6. Analysis of expenditure by activities (continued)

Analysis of support costs

	Annual conference 2022 £	Total funds 2022 £
Bank charges	813	813
NSF Membership services and database fee	2,920	2,920
Other support costs	1,596	1,596
Irrecoverable VAT	8,234	8,234
Independent examination fees - governance cost	1,565	1,565
Association management	10,000	10,000
	<u>25,128</u>	<u>25,128</u>
	Annual conference 2021 £	Total funds 2021 £
Bank charges	211	211
NSF Membership services and database fee	2,920	2,920
Other support costs	178	178
Independent examination fees - governance cost	1,300	1,300
Association management	10,000	10,000
	<u>14,609</u>	<u>14,609</u>

7. Independent examiner's remuneration

	2022 £	2021 £
Fees payable to the charity's independent examiner for the preparation and independent examination of the charity's annual accounts	<u>1,330</u>	<u>1,300</u>

8. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2021 - £NIL).

During the year ended 31 March 2022, expenses totalling £707 were reimbursed or paid directly to 1 Trustee (2021 - £NIL). Expenses reimbursed related to cost of board meal.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

9. Debtors

	2022 £	2021 £
Due within one year		
Trade debtors	7,629	252
Other debtors	253	3,363
	<u>7,882</u>	<u>3,615</u>

10. Creditors: Amounts falling due within one year

	2022 £	2021 £
Trade creditors	44,404	1,755
Other taxation and social security	474	-
Accruals and deferred income	2,045	2,600
	<u>46,923</u>	<u>4,355</u>

11. Financial instruments

	2022 £	2021 £
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>143,518</u>	<u>103,432</u>

Financial assets measured at fair value through income and expenditure comprise bank balances.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

12. Statement of funds

Statement of funds - current year

	Balance at 1 April 2021 £	Income £	Expenditure £	Balance at 31 March 2022 £
Unrestricted funds				
General Funds	102,692	61,988	(60,203)	104,477
Restricted funds				
Restricted Fund	-	39,207	(39,207)	-
Total of funds	102,692	101,195	(99,410)	104,477

Statement of funds - prior year

	Balance at 1 April 2020 £	Income £	Expenditure £	Balance at 31 March 2021 £
Unrestricted funds				
General Funds	112,619	11,250	(21,177)	102,692
Restricted funds				
Restricted Fund	-	21,000	(21,000)	-
Total of funds	112,619	32,250	(42,177)	102,692

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

13. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2022 £	Total funds 2022 £
Current assets	151,400	151,400
Creditors due within one year	(46,923)	(46,923)
Total	<u>104,477</u>	<u>104,477</u>

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2021 £</i>	<i>Total funds 2021 £</i>
Current assets	107,047	107,047
Creditors due within one year	(4,355)	(4,355)
Total	<u>102,692</u>	<u>102,692</u>

14. Related party transactions

Several trustees attended the annual conference in the year and paid the appropriate attendance fee at the same rate as other delegates. There were no other related party transactions during the year.